Are you above the legal age to view this content in your province/state?

Home / Industry News / Global cannabis testing market to grow 13.4% through 2025

Global cannabis testing market to grow 13.4% through 2025

Global cannabis testing market to grow 13.4% through 2025

19 Agust, 2020, UK (HealthEuropa)- Increasing demand for safety and high-quality medical products has added impetus to cannabis testing services and will contribute to the growth of the global cannabis testing market, which is set to grow by 13.4% by 2025.

According to a Global Market Insights, Inc., report, the growing prevalence for these tests by cultivators and manufacturers will bolster the industry trends. The Bureau of Cannabis Control, as of March 2018, had issued about 26 temporary licenses to testing laboratories in California.

Additionally, rising investments and legalisation of cannabis in many countries, along with soaring recognition for R&D in exploring the medical benefits concerning cannabis will significantly contribute to the market revenues in the next few years. For example, UJI Capital, an equity firm, donated around USD $9m (€7.54m) to Harvard and Massachusetts Institute of Technology for research on cannabinoids.

It has been estimated that the global cannabis testing market size is likely to surpass $2bn by 2025. Higher costs of testing equipment, absence of uniform testing standards, and complications associated with regulatory norms are some of the characteristics hindering the market forecast slightly.

Deployment of chromatography technology

In 2018, chromatography powered cannabis testing industry registered close to 62.4% share of the total annual revenues. This can be attributed to high sensitivity and ease of separation, among various other advantages. Also, the adoption of technologically advanced equipment for carrying out several analytical and quality tests of cannabis will witness a surge.

Government-backed initiatives to ensure safety

Potency testing market for cannabis is estimated to grow at more than 13.9% CAGR by 2025. A hike in hemp and cannabis cultivators coupled with strict regulations can be accounted for this estimate.

Based on applications, cannabis testing laboratories brought in over $599.5m in 2018 across regions that legalised the medical use of cannabis owing to the rising demand for the testing of samples.

Extending support from various governments for funding enhancements in cannabis testing infrastructure with stringent norms and regulations to ensure patient safety and product quality with the legalisation of cannabis will also drive the market prospects for potency testing and cannabis laboratories.

US and the Netherlands to emerge as key markets

Geographically, the Netherlands is one of the leading manufacturers and suppliers of cannabis and hemp that is employed in medical use globally and is believed to surpass a growth rate of 20.2% CAGR through 2025. With the regulations and medical demands for cannabis in place, the testing services will witness numerous growth opportunities.

In 2018 the US cannabis market gathered the largest market share, pegged at around 61.2% of the total remunerations. Inclining recognition for cannabis with expanding legalised cultivation activities and testing laboratories is set to stimulate regional growth

The COVID-19 crisis has also impacted the therapeutic significance of cannabis. A recent study reveals that the active compounds in this product have healing properties that could potentially treat infections caused by the virus and can be mastered as an antiviral drug. Researchers and scientists at the University of Nebraska and the Texas Biomedical Research Institute are citing extended research on cannabis-derived CBD to treat the hazardous lung inflammation caused by the novel virus.


Investment Value Finders specializes in providing opinions and information on stocks to individuals who wish to receive them. Our reports are construed for information purposes solely and are distributed free of charge to individuals who wish to receive them.

Investment Value Finders does not promote, condone or advocate licit or illicit drug use. Investment Value Finders cannot be held responsible for materials or contests posted on its website pages, or pages to which we provide links, which promote, condone or advocate licit or illicit drug use or illegal activities.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE. We are not registered as a securities broker-dealer or an investment adviser. We are neither licensed nor qualified to provide investment advice.

Investment Value Finders occasionally receives direct compensation for hosting links (or other* advertisements) to third party content that may be subject to disclaimer pursuant to Section 17(b) of the Securities Act of 1933. For those instances where the link text contains company or stock-specific mention, we provide the following list of compensation received in order to ensure full disclosure and transparency.

Investment Value Finders is intended for those 21+ years of age only!

Check Also

Stocks and Founds that are overexposed To Russia And Ukraine

Stock markets worldwide have been in red since Russia began its invasion of Ukraine last …